2.2 Z!' Õ z O [6Ñ L k ú } q =6Ñ L õ å

… } Ö6Ñ

zõO[6Ñk				85,487	
õO[ã;Hx6ÑÑk				F2+X	
6Ñ0	6ÑWCX	16Ñ » (%)	16Ñ	199L8ÑGÿ	CÑ5 ,6ÑGÿ
:8QÖ0ÏåLe	¼MŽ9#	39.83	920,641,314	0	
HKSCC NOMINEES LIMITEDÅ	F#	17.42	402,637,600	0	Z
~/n*H0 M8	Z	1.39	32,189,766	0	
]-K8KF91,6ÑñCt*H	Z	0.78	18,000,000	0	
~/n*H004	Z	0.66	15,222,881	0	
]-*A1K8ÑñCt*H	Z	0.64	14,880,000	0	
F1ñCt*H	Z	0.63	14,500,000	0	
]-K8w$@KTV6ÑñCt*H	Z	0.54	12,577,314	0	
# ç1L6Ñ9L6É4Ð 019LÉ FH002 "Ú	Z	0.45	10,324,851	0	
:8cÏåLe	¼MŽ9#	0.37			

2.3 ×6Ñ6Ñ L F ÎLu × f ê $ õ å

¶F2+X F2+X

9Ã 1Ñ*6 rAØAê > 6 À

(0) Õ z O µ4ÿ:U õ å

2014 È34 *F'Ã O n5C,U+ Ç

1 15K

4 U*6% 6w O Î

KÃ P ÕU 51FOÃ

ÕU A1 553,853.93 7sÈ³ 2013 Ê Ì¯ 22.83%×

FP U A1 338,912.72 7sÈ³ 2013 ÊÎ

Ì¯10.62%Ä U A1 55,035.90 7sÈ 2013 ÊÌ¯ 231.69%Ä

ÕU 4

A1

Ñ	2014 ¤ 1 8# 6 8 :U	2013 ¤ 1 8# 6 8 :U	%Å
FP	338,912.72	306,365.28	10.62
K0	75,942.24	71,055.63	6.88
Ñ	55,035.90	16,592.58	231.69
FP	71,306.21	43,179.02	65.14
6	11,815.00	12,964.57	-8.87

+a¾ 2013 Ê L t,- Ñ H 6Ñ A 5 , A É A1

59,496.29 7s A1 44,622.22 7sÈ 2014 ¤ U

1 133,115.99 7s É A1 133,816.75 7s 2 6Ñ,

100,201.46 7s [E³ 2013 Ê+ L U Ì M W ;õ

51:wC È 2014 ¤ 2 6Ñ, M W ;õ

A1 66,979.11 7sÈ³ 2013 Ê Ì¯ 34.54%Ä

ÕU 5) yMF K, C tÈ 9x Ø ¶ +O(™

/f9 9 D U FP D Y cB'Eî 24 N 5

5¾ CY 4 N MF, Õ Ç O(2 K 3R K8 ‰^

0GÉÊÝwr9ÇÐÈÊÕO[ÈÆX9ÝÛN© 125 NÆ

ÈÆÆÊÝÊt1J Saladax Biomedical, Inc.,Ê

ÆÐÇÉEEF¾ ¶ 5-"OoW¾Êr-ÄÊÆÆÅ

3[yGÊr-ÄÊÆÆÅGÊr-ÄÊÆÆÅ

9ÈÐÆÝÉr,ÊÄ

ÆÕÈÇÉ0WÞk¶Ñ¶Ât ÈÆÑ*Ct€Ç÷ 22,362

75¾ÊFNÆÐF0tÇ}ÆUFC¾Ê¤u

,Q1k¾ÊpÆÐ¼ÊÇÉLö*@ ,´ "ÊÐQ

1k¾Ê¤C05¼8k-(58,k¾ÊH+ÞpÄ

ÈÆÞ-LuFH+ÆÕÈÇÉt¶Æ@ÑÃ

FOÆÝXGy+ÐÆÊFAuÉr,ç1J miacom Diagnostics GmbH

21,304 6ÊÆÑ miacom Diagnostics GmbH Ê¤ ¾ÆÑ 37¾ÆÅ

E¾2,ÝOK01J Nature's Sunshine Products, Inc.1ÆÇÑÂÔ]ÆÊCt

€Ç÷ 4,626 7 5¾ÂÔ] Nature's Sunshine Products, Inc. 4Ö15%,6ÊÑ Ä

9ÊFP>Ð

Õ z O µ È \Lö 9Ÿ ñ fFP >.D J Ñ Î)à:U J f • ê"A 1 338,912.72 7sÈ³ 2013

Ê Ê¯ 10.62%Ê6G5ÊA1 48,036.04 7sÈ³ 2013 Ê Ê¸} 8.59%× Î

)ÊGÆA1 48,514.00 7È 2013 Ê 7.67%Ä

ÆÕÈÇÉÊÐFP>ÐÊ510cÊ¯ ÈÊF4¾ULO*AÊF0¦

¸Ä 2014 ¤ÈÊ15Ñ+5ÆxBR¾ÊFÇ21y+î÷ðë¶Ñ¶

ÆÊK0^ 1EÊÆÐÊ15Ñ+5+î÷ðë¶ÑK0f¼ Ê¯

30.12%ÆxBR¾ÊFƒî÷ðë¶ÑK0f¼ Ê¯ 12.19%Ñ+î÷õ

"ë¶ÑK0f¼ Ê¯ 58.41%Ê¾15Ñ+5+î÷ðë¶ÑHM

DÆÊDÆxBR"ë¶ÑH0ÊMŽ((w,Å0ÊKÊÄ +a¾

(x GMP iFP€G6+O¾ÆÅXOÈ A7FÞcÊ-¾6GúÈ ¾M

G6Ê*6È v 1ÆF@ÊÆ

ÕÒÈ¤ÇÑ¶ÎÃ0fÖ

Ø¤ 1/ØA1

9ÎFP¤Ð	2014 ¤ 1 8# 6 8	2013 ¤ 1 8# 6 8	¼Ø %Å
ø1Ñ+5+î÷ðë¤Ç¶ñõ (# 1)	31,722.83	24,379.91	30.12
]ØZ3+5+î÷ðë¤Ç¶ñõ (# 2)	33,055.74	35,397.69	-6.62
þ3+5+î÷ðë¤Ç¶ñõ (# 3)	8,694.61	12,124.72	-28.29
LxBRøFf÷î÷ðë¤Ç¶ñõ (# 4)	71,343.82	63,594.05	12.19
Ç+î÷ðë¤Ç¶ñõ (# 5)	56,428.85	35,622.65	58.41
(# 6)	43,382.35	49,659.93	-12.64

¤OK¯ 23.01% MBÇ5F0PÈÆO[¿W9Ö"9M&

9Ç 1,944 Æ

kÑ

2014 ¤ ÈÖ@"¿Q1kÑ4¿C05¼8k

L’(58,kÑH+3pÈÖÑÑUF7-ËAÈ $

Fk¿G1ÑÈ@Ö h1¿ÈÈHÖÈkÑ

ÆÖ¿5,8kW:m@¿ÖP2FkÑ

*.p¿k# 6¡T k8ÆÖ6¡T¿Ök_ÆÈ

LkÑ¿FÄ 2014 ¤ È6,kÑÑ•

ê A1 55,035.90 7s ÆÖ[È6,ÑA kÑÑk¿µ

k8AÑÊ 2,090 PÄ

FÈÆÑ*Ct€¿÷ 22,362 75³6¿ÑFN© È 01Ø

Ö¿Q1kÑ¶(¼e’ (United Family Hospital)¼¿55

,¾pÄ 2014 ¤ È Ñ¼eK¯x)8,Ÿ

ÎK¯Ä ÇÖ¿• 10,534 75³È³ 2013 ¤OÇ¯ 20.33%È

/¶5Î,Q1kÇ0"r¼¿Ä

kÆÇ

2014 ¤ È5EÆVÅt¿8ÖÑÆÇ¶

¿ÑÖ[Å¶t@ÑÖÃ ¯XG49HÊ

,¿FAÚr,ç1J miacom Diagnostics GmbH 21,304 6ÑÑ miacom

Diagnostics GmbH ÑÇ 37ÈÖ[u2¿AÚ,8È

WLÆÚu2ÑÆÚ¶t

1J Saladax Biomedical, Inc.,ÑÖÈ5EÆF¼ ¶ 5-"O

oW¿r-ÄÑÇÖÖÖr-ÄÑÖÖ¿Ä

3[yG# Îr-ÄÑÇÖÖ0ÆÚr,ÆÄ

kÇÑÖÈ0 Alma Lasers ,Ñ5¿F)

Chindex Medical Limited ÑÇÄ 2014 È Alma Lasers F0Ñ¿X

+¿ÖÆÚd"ë¯Ç¶¼¿M%ÿ¾ 2014 ¤ 7 89ç

5¾ FDA Ñ 1470 4ÆE0%ÿ3+5¾ 2014 ¤ 7 8F÷ CE AÖÄ

ÇÖÆÚÇF¿ÑU¿A1 71,306.21 7s³ 2013

65.14%

Alma Lasers 3

2013

17.23%

11,815.00 7s

2013

8.87%

B3¤ *6

Õ z O µ È \Lö Q ÖGý?ö)ß ³ Ô Ã6| J • ç > ¹ ˜ Ä1°0 EHS

EHS EHS EHS

EHS EHS

EHS EHS EHS

EHS EHS EHS

EHS

2013 ÐnCS+

3¶nCS+

nCS+

nCS+

nCS+

nCS+

(¼) k:U J Ñ 6 À

1 ÃCR Ñ Õ>˜-(£0 - Ø 6 À>˜

… } Ö ê"A 1 7s

0-	Ò	:¢	Ø	%Å
:UJ•	553,853.93	450,928.94	22.83	
]ÖÑ	552,023.43	446,104.39	23.74	
:U@\	318,661.63	251,425.13	26.74	
]Ö :U@\	317,789.74	249,486.52	27.38	
K0Ci+X	101,729.76	88,568.59	14.86	
1Ñ6Ci+X	78,141.36	60,504.28	29.15	
]ÖDCi+X	25,407.15	16,438.13	54.56	
DCi+X1Ñ6Ci+X	52,734.21	44,066.15	19.67	
CRÑi+X	15,967.63	18,824.90	-15.18	
4¡UÆO,)HGÑÍ	40,367.34	31,147.90	29.60	
ÆO,)HGÑÍ	-19,500.44	-171,559.91	-88.63	
1ÆO,)HGÑÍ	77,604.94	30,681.56	152.94	
.D*_	29,654.97	18,265.19	62.36	

)HGÑÍ

6ñ						
9 Lÿÿÿ

		Ý						

Ëð ¹To9Ÿ ¿ÆÂÎÂÎzK0

2 Ã ð Y#Ö Ã ÅCt f,ú) \Lö ð Y#Ö ¡ ýEî 10% : ò6Ñ œ (,´4ÿ:U õ å ú J5

… } Ö 7 s 1/ÿ ßA1

(œ θ	Ñ WCX	¥= Ñ	¥t\	£t×	©t×	:U•ƒ	:U¥ð	¥ð
-9Ÿ Å	¥Ÿ ©t	F¥ÉX fr9ÕÐ 3P¡Ã@9¥ÕO F¥ÃÑŸ ÑÃ C¥ÐÕ 1Ñ6Ct× G÷4ÃÇh CÑM8K1Ã (¥ÐF1é(¥ÐÑ	10,000.00	11,314,261.20	3,078,216.72	9,483,567.26	289,762.56	231,525.28

3 Ã \ ¤ Ö Ç ¼ 45ž € œ (,´ õ å È 5 Ç ¼ 45ž,´- ,´ Ã é ? ú) \Lö ¤ ƒ+O ×

4ÿ:U ¼ J5 ,´ ¡ ý

… } Ö 7 s 1/ÿ ßA1

€ œ (=0	Ç é ?	ðCt × Ä Z8# 2014 ¤ 6 8 30 Å	ð Y#Ö ÄC] ¦ 8# 2014 ¤ 6 8 30 Å	¦C]
Tô"ã9Ÿ J	6Ñ sEœAÙ	-228.43	-	2014 ¤ 6 8 16

… } Ö 7 s 1/ÿ ßA1

€ œ (=0	45ž é ?	45ž ðCt ×	Õ z O M8# 45ž ð Y#Ö	45ž
ç € f9Ÿ	6Ñ sEœAÙ	3,434.32	10.31	2014 ¤ 1 8 29

(Ä) h ó1 ¹ Ë 6 À

\Lö " X] -9Ÿ ñ 2 j 0 §%Œ Ë ¼ @K¯ Ë,´ Ä W+î+õN¶ Ä ó>p1Ñ ÃàLx BR ú#¸ F

Fƒ Ã] Ò/Ž4ÿ3+5 Ã>p#â3+5 Ã Ç O 1y Å ’ @ ¶" E³ ¼ ´,´ × ñ 3 p Ä \Lö h ó k9Ÿ ×

ñ X 48 ,´4ö 6 2 jN¶ G- § 9N¶ x,´ H ï Ä 2013 ÐK0NÉ¡ƒ¼

3+G"Eî 15 Ä

L ö@-LuF,.D3p Ä.D7-

9*0 F,.D 3+ K 9 L 9

9 yN PQx,.D 0[9 N© 125 È

23 Ø Xc dBP 1 0 ä@ £5 ³ Lö q^3 Aî 9 Q 3

AÑ 6 L 54 U 5 15w 8 p O

.D Eî 825 EH+6, 8 Ct 1

s047L¾

%

FF

2014 æ

+"

L

"ë

2014 æ

9

2014 æ

-Lu

9

2014 æ

W

,DO

(6

J¼

W

9

2014 æ

5¼

6F0

k¥Ç/6¡T]ðÆÈK15w/þ¼k€ Ñ£4Ø3$¼

Ìþ56Ø20ÇÈ"2CÆÈNÇ*

AÇ£±"r¸ÈkÇÑ¡þÈ66FÆÈ5}ÂÈF55_

1ÇÈÂÈ1k¥ÇÈÈD.

rÇQÆFÑÈW¡8¢Q1k¥ÇÑ

ÈÁÉÇ¡

2014 æÈ55ØÁÆÈÑÆÈÈÁ

Æ5¡þK055ÇÈK0LO±ÁÈÑ5 2014 ÈFÆ

þÁÈ2¡NÍ ð±"r-ÆH/ÁÈÇÂtjÄ

2014 ¥ÈÈÈÑFk¢ÇDÃPK¼0Ä Alma Lasers

6F0Ð k¥Ç¢Ç 0K¼0È 0ÈRÆÈQK

ÆÈÆÈ ÈÈ55U-LuFÈM,'HÐ,´

È1ÆÈ,*.p:WÈ1,ÆÈÈÇ

ÆQÎKÄ

Èt

\Lö 65 5 … ³ µ F,´=½Ct$PFƒ È H F \Lö ,´=½Ct5 ´ ¼ j Ñ5 ´ ÈL} ~CR Ñ @

\ È Ø Ø \Lö F 0!• Ð j h ó1 ¹7- Ë *Aî È *>| JN¶ x ` } Ä

(›) MŽ LöCtH N©- õ å

1Ã ÇÒÈ 2014 ¹0Qd8ÑWÈtÈÐÈÇCt€µ

EÈA1 186,607.98 7sAÈÈ19,¶To9ÏÝ 28.146%6ÑÈÒ66TÇf

ÈÈÐÈÇCt€ÈÈA1 152,490 7sAÈÈo9ÏÝ 23%6ÑÈ

N©¼ 2014 ¤ 6 8 4 Ç@ÆÈÑÈÈÒÈÈo9ÈÇQ)ð

ÈÈA1 15,687.44 7sÈÈo9ÈÇQ)ÈÈÍ´ 11.72%Ä

2Ã ÇtÈÐ ÊÈ÷ 22,362 75¾µ19,5ÈÂÑ 3,157,163 6Ñ

A 26ÑÈÂÈFÈÈ÷ 4,500 75¾AÙ Chindex Medical Limited 30%

6ÑÈÑÆÈÂÑWÈÈÈÂ Chindex Medical Limited

6[j2(ÇQ)ÈÐ ÈA1 0 ú 318.70 7sÈÈÂ Chindex Medical Limited

j2(ÇQ)ÈÈÍ´ 0%ú 0.24%Ä

Ã ¦ Gý W »N©

1Ã 2013 ¤ 12 8 20 è 2013 ¼0Qd8ÑWÃ 2013 ¼0Q A 6Ñ‹6Ñ

Lu 2013 ¼0Q H 6Ñ‹6ÑÑ

fW6Ñ‰ÃÑÝyxAÒÅ 2014 ¤ 1 8 7 è

AÞ W6Ñ‰ÃÑ¸(Ñ

2014 ¤ 1 8 7 uA 27 ‰ÃÑ 393.5 76Ñ A 6ÑW6Ñ

¾ 2014 ¤ 1 8 20 ¼Ãñ¸Ã519LC S+(6¼ A 6ÑW6Ñ

¸Ã5Ä

2Ã 4ý-Ãñ Ã -Aè [2014]240 'Ý (Lö)6Ñ9L

F:2FCt6 ÃA 6

67,214,000 6Ñ H 6ÑG¾ 2014 ¤ 4 8 3 Ä

3Ã 2013 ¤ 10 8 23 è SELLAS Clinicals Holding AG 1Ò

Fotagliptin Benzoate bG "p Ã Ê

Pan-HER InhibitorsÄ Pan-HER Ã Ê

2014 ¤ 6 8 30 È SELLAS Clinicals Holding AG 3Ã 800 7

150 7 9' Ê

2014 ¤ 6 8 30 Ã SELLAS Clinicals

Holding AG * 2013 ¤ 10 8 24 ú 2014 ¤ 7 8 1

a:F Ã

5Ä http://www.sse.com.cn Ã Ê

CtF Ê

Ä Ã #¹ úCR Ñ Õ z,´-(£ »N©

1Ã z Ll C]¶ To9Ý 23%,6 16Ñ a 70% # 93%Ä” Õ

zOµ Ñ Ý ¼ Ã 9 $ T Ý ¼ 9h8Ý HB‘ È

CRÃ

2Ã 2014 ¤ 1 8 # 3 8È RoGf Ã \ 39 ' --Ã

\ 40 ' --8Ã \ 41 ' --Ã

Ã \ 30 ' --CÃ \ 9 ' --Ã

I1\ 33 ' --8Ã \ 2 ' --KÕ6Ã Ê 7 NÃ w